Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification

22Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Background. Resolving the differential diagnosis between brain metastases (BM), glioblastomas (GBM), and central nervous system lymphomas (CNSL) is an important dilemma for the clinical management of the main three intra-axial brain tumor types. Currently, treatment decisions require invasive diagnostic surgical biopsies that carry risks and morbidity. This study aimed to utilize methylomes from cerebrospinal fluid (CSF), a biofluid proximal to brain tumors, for reliable non-invasive classification that addresses limitations associated with low target abundance in existing approaches. Methods. Binomial GLMnet classifiers of tumor type were built, in fifty iterations of 80% discovery sets, using CSF methylomes obtained from 57 BM, GBM, CNSL, and non-neoplastic control patients. Publicly-available tissue methylation profiles (N = 197) on these entities and normal brain parenchyma were used for validation and model optimization. Results. Models reliably distinguished between BM (area under receiver operating characteristic curve [AUROC] = 0.93, 95% confidence interval [CI]: 0.71–1.0), GBM (AUROC = 0.83, 95% CI: 0.63–1.0), and CNSL (AUROC = 0.91, 95% CI: 0.66–1.0) in independent 20% validation sets. For validation, CSF-based methylome signatures reliably distinguished between tumor types within external tissue samples and tumors from non-neoplastic controls in CSF and tissue. CSF methylome signals were observed to align closely with tissue signatures for each entity. An additional set of optimized CSF-based models, built using tumor-specific features present in tissue data, showed enhanced classification accuracy. Conclusions. CSF methylomes are reliable for liquid biopsy-based classification of the major three malignant brain tumor types. We discuss how liquid biopsies may impact brain cancer management in the future by avoiding surgical risks, classifying unbiopsiable tumors, and guiding surgical planning when resection is indicated.

References Powered by Scopus

The 2021 WHO classification of tumors of the central nervous system: A summary

6464Citations
N/AReaders
Get full text

DNA methylation-based classification of central nervous system tumours

2025Citations
N/AReaders
Get full text

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

1106Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Classification of Brain Tumors by Nanopore Sequencing of Cell-Free DNA from Cerebrospinal Fluid

28Citations
N/AReaders
Get full text

Epigenetic clocks in neurodegenerative diseases: A systematic review

17Citations
N/AReaders
Get full text

Cerebrospinal Fluid cfDNA Sequencing for Classification of Central Nervous System Glioma

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zuccato, J. A., Patil, V., Mansouri, S., Voisin, M., Chakravarthy, A., Yi Shen, S., … Zadeh, G. (2023). Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. Neuro-Oncology, 25(8), 1452–1460. https://doi.org/10.1093/neuonc/noac264

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

63%

Researcher 3

38%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

50%

Biochemistry, Genetics and Molecular Bi... 2

25%

Chemistry 1

13%

Arts and Humanities 1

13%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free